Glycemic control
The baseline HbA1c and fasting plasma glucose levels were comparable between the two groups. The HbA1c level significantly decreased after 24 months of treatment compared to the baseline value in the ipragliflozin group (7.4 ± 0.8% vs. 7.0 ± 0.9%; P < 0.01), but not in the control group (7.4 ± 0.7% vs. 7.3 ± 0.7%; P = 0.27). However, there was no significant difference between changes in HbA1c levels in the two groups (7.4 ± 0.8% vs. 7.0% ± 0.9% in the ipragliflozin group and 7.4 ± 0.7% vs. 7.3 ± 0.7% in the control group; P = 0.08 Table 